Personalized Medicine in Pancreatic Cancer: The Promise of Biomarkers and Molecular Targeting with Dr. Michael J. Pishvaian
V Cortiana, RH Abbas, H Chorya, J Gambill… - Cancers, 2024 - mdpi.com
Simple Summary Pancreatic cancer, with its increasing incidence, is predicted to become
the second deadliest solid tumor by 2040, urging for improved diagnostic and treatment …
the second deadliest solid tumor by 2040, urging for improved diagnostic and treatment …
Selection of patients with pancreatic adenocarcinoma who may benefit from radiotherapy
IS Jan, HJ Ch'ang - Radiation Oncology, 2023 - Springer
Despite combination chemotherapy demonstrating a positive effect on survival, the clinical
outcomes of pancreatic adenocarcinoma (PDAC) remain poor. Radiotherapy was previously …
outcomes of pancreatic adenocarcinoma (PDAC) remain poor. Radiotherapy was previously …
Recent Advances in Metal-Based NanoEnhancers for Particle Therapy
YC Chuang, PH Wu, YA Shen, CC Kuo, WJ Wang… - Nanomaterials, 2023 - mdpi.com
Radiotherapy is one of the most common therapeutic regimens for cancer treatment. Over
the past decade, proton therapy (PT) has emerged as an advanced type of radiotherapy …
the past decade, proton therapy (PT) has emerged as an advanced type of radiotherapy …
Differential Sensitivity to Ionizing Radiation in Gemcitabine-Resistant and Paclitaxel-Resistant Pancreatic Cancer Cells
PP Che, A Gregori, C Bergonzini, M Ali… - International Journal of …, 2024 - Elsevier
Purpose Chemoresistance remains a major challenge in treating pancreatic ductal
adenocarcinoma (PDAC). Although chemoradiation has proven effective in other tumor …
adenocarcinoma (PDAC). Although chemoradiation has proven effective in other tumor …
The current role of radiation in pancreatic cancer and future directions
CS Hill, JM Herman - Clinical Colorectal Cancer, 2023 - Elsevier
Survival outcomes for localized pancreatic adenocarcinoma remains poor. Multimodality
therapeutic regimens are critical to maximizing survival outcomes for these patients, which …
therapeutic regimens are critical to maximizing survival outcomes for these patients, which …
Evaluating the clinical efficacy and safety of concurrent chemoradiotherapy with cisplatin and nab-paclitaxel in postoperative early-stage cervical cancer
N Zhao, Y Li, X Chen, J Ma, W Luo, Y Li - Journal of Cancer Research and …, 2024 - Springer
Objective A preclinical study showed that nab-paclitaxel acted as a radiosensitizer and
improved tumor radiotherapy in a supra-additive manner. In this study, we aimed to evaluate …
improved tumor radiotherapy in a supra-additive manner. In this study, we aimed to evaluate …
Nanotechnology in cancer therapeutics, diagnosis, and management
D Hazarika, S Sarma, P Shankarishan - BioTechnologia. Journal of …, 2024 - agro.icm.edu.pl
Nanotechnology presents an exciting opportunity in cancer research by offering significant
advancements in therapies, diagnosis, and management. It possesses unparalleled …
advancements in therapies, diagnosis, and management. It possesses unparalleled …